LVAD: Blood-pressure Measuring in Patients Carrying a Left Ventricular Assist Device

Sponsor
University Hospital Inselspital, Berne (Other)
Overall Status
Completed
CT.gov ID
NCT03458988
Collaborator
(none)
30
1
1
34.1
0.9

Study Details

Study Description

Brief Summary

To prove the novel device is able to reliably detect pulsatility in patients with CF-VADs and to analyze whether pre-programmed intrinsic pulsatility of the 3rd generation CF-VADs can also be picked up. The study is not designed to measure blood pressure.

Should this pilot study be successful in detecting enough pulsatility a follow-up study would then try to transfer the results into blood-pressure values with the help of comparators in order to identify an easier and more reliable method to measure BP in CF-VAD patients. .

Condition or Disease Intervention/Treatment Phase
  • Device: Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)
N/A

Detailed Description

The number of patients supported by left ventricular assist device (LVAD) is increasing as durable mechanical support has become widely available for end stage heart failure as destination therapy and as bridge to transplantation. The accurate measurement of blood pressure (BP) as well as the recognition and management of hypertension in patients with LVADs is an essential component of optimal clinical care. Hypertension is an established long-term risk factor for cardiovascular disease. The measurement of BP and the management of hypertension in patients with CF-VADs can present unique challenges. Patients with LVADs often do not have a palpable pulse, and therefore traditional BP measurement by auscultation or automated cuff is less reliable. Conventional occlusive BP measurement is able to to pick up signals in approximately 50% of cases due to coincidental phases of pulsatility. The arterial line is the gold standard, but is an invasive procedure and not practical for routine outpatient use.

Although efforts are underway to identify an easier and more reliable method to measure ambulatory BP in these patients not one has been able to match the quality of an invasive arterial line.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Pilot Study to Validate a Novel Blood-pressure Measuring Device in Patients Carrying a Left Ventricular Assist Device
Actual Study Start Date :
Feb 27, 2018
Actual Primary Completion Date :
Oct 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: All patients

Nellcor™ Adult SpO2 Sensor

Device: Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)
Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
Other Names:
  • Nellcor™ Adult SpO2 Sensor
  • Outcome Measures

    Primary Outcome Measures

    1. RR (Riva Rocci, indirect blood pressure measurement) in LVAD [10 min blood measuring]

      Detect pulsatility in CF-VAD (Continuous flow- ventricular assist device) patients sufficient to calculate comprehensible blood-pressure values in future follow-up studies

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients carrying one of the two third generation CF-VADS (Heartware HVAD, Heartmate
    • Patients >18y

    • Good understanding of written and oral German

    • Signed informed consent

    • Scheduled for routine outpatient appointment.

    Exclusion Criteria:
    • In the population of the outpatient clinic's CV-LVAD patients no known exclusion criteria exists

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Bern Bern Switzerland 3010

    Sponsors and Collaborators

    • University Hospital Inselspital, Berne

    Investigators

    • Principal Investigator: David Reineke, MD, University Hospial Bern, Cardio Vascular Surgery

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital Inselspital, Berne
    ClinicalTrials.gov Identifier:
    NCT03458988
    Other Study ID Numbers:
    • 2017-01570
    First Posted:
    Mar 8, 2018
    Last Update Posted:
    Nov 23, 2021
    Last Verified:
    Nov 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital Inselspital, Berne

    Study Results

    No Results Posted as of Nov 23, 2021